JP2021523240A5 - - Google Patents

Info

Publication number
JP2021523240A5
JP2021523240A5 JP2021514291A JP2021514291A JP2021523240A5 JP 2021523240 A5 JP2021523240 A5 JP 2021523240A5 JP 2021514291 A JP2021514291 A JP 2021514291A JP 2021514291 A JP2021514291 A JP 2021514291A JP 2021523240 A5 JP2021523240 A5 JP 2021523240A5
Authority
JP
Japan
Prior art keywords
formula
hydrogen
ring
pharmaceutically acceptable
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514291A
Other languages
English (en)
Japanese (ja)
Other versions
JP7344959B2 (ja
JP2021523240A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032127 external-priority patent/WO2019222154A1/en
Publication of JP2021523240A publication Critical patent/JP2021523240A/ja
Publication of JP2021523240A5 publication Critical patent/JP2021523240A5/ja
Priority to JP2023142664A priority Critical patent/JP7656669B2/ja
Application granted granted Critical
Publication of JP7344959B2 publication Critical patent/JP7344959B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514291A 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 Active JP7344959B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023142664A JP7656669B2 (ja) 2018-05-15 2023-09-04 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671753P 2018-05-15 2018-05-15
US62/671,753 2018-05-15
PCT/US2019/032127 WO2019222154A1 (en) 2018-05-15 2019-05-14 Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023142664A Division JP7656669B2 (ja) 2018-05-15 2023-09-04 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021523240A JP2021523240A (ja) 2021-09-02
JP2021523240A5 true JP2021523240A5 (enExample) 2022-05-11
JP7344959B2 JP7344959B2 (ja) 2023-09-14

Family

ID=66690981

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021514291A Active JP7344959B2 (ja) 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP2021514292A Active JP7343571B2 (ja) 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP2023140718A Pending JP2023164905A (ja) 2018-05-15 2023-08-31 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP2023142664A Active JP7656669B2 (ja) 2018-05-15 2023-09-04 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021514292A Active JP7343571B2 (ja) 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP2023140718A Pending JP2023164905A (ja) 2018-05-15 2023-08-31 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP2023142664A Active JP7656669B2 (ja) 2018-05-15 2023-09-04 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法

Country Status (20)

Country Link
US (6) US12258335B1 (enExample)
EP (4) EP4349332A3 (enExample)
JP (4) JP7344959B2 (enExample)
KR (3) KR102861502B1 (enExample)
CN (3) CN119462623A (enExample)
AU (3) AU2019269409B2 (enExample)
BR (1) BR112020023269A2 (enExample)
CA (2) CA3100319A1 (enExample)
DK (2) DK3793992T3 (enExample)
ES (2) ES2978192T3 (enExample)
FI (2) FI3793995T3 (enExample)
HU (2) HUE066627T2 (enExample)
LT (1) LT3793995T (enExample)
MY (1) MY199200A (enExample)
PL (1) PL3793995T3 (enExample)
PT (2) PT3793992T (enExample)
SG (2) SG11202011316RA (enExample)
SI (1) SI3793995T1 (enExample)
TW (3) TWI798435B (enExample)
WO (2) WO2019222154A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
KR102861502B1 (ko) * 2018-05-15 2025-09-18 포시 파마슈티컬스 유에스에이 인코포레이티드 기질 금속단백분해효소 (mmp) 억제제 및 이의 사용 방법
CN115667227B (zh) 2019-11-14 2024-11-01 逸达生物科技股份有限公司 基质金属蛋白酶(mmp)抑制剂及其使用方法
JP2024520818A (ja) * 2021-06-08 2024-05-24 フォアシー ファーマシューティカルズ カンパニー リミテッド 急性呼吸促迫症候群を処置するためのｍｍｐ阻害薬の使用
EP4351566A4 (en) * 2021-06-08 2025-04-23 Foresee Pharmaceuticals USA, Inc. SAFE ADMINISTRATION OF MMP-12 INHIBITOR
WO2023110473A1 (en) 2021-12-14 2023-06-22 Basf Se Heterocyclic compounds for the control of invertebrate pests
EP4198033A1 (en) 2021-12-14 2023-06-21 Basf Se Heterocyclic compounds for the control of invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482618A1 (fr) 1980-05-16 1981-11-20 Inst Corps Gras Iterg Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
AU1817700A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
AU4882101A (en) 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
KR20030082990A (ko) * 2001-03-15 2003-10-23 아스트라제네카 아베 메탈로프로테이나제 억제제
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
EP1394159A1 (fr) 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US7041693B2 (en) 2002-10-04 2006-05-09 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
US7132432B2 (en) 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
DK1789036T3 (da) * 2004-08-19 2011-06-27 Quest Pharmaceutical Services 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dion og analoger som inhibitorer af makrofagelastase
JP5357365B1 (ja) 2011-12-21 2013-12-04 パナソニック株式会社 データ処理装置、データ送信装置、データ処理システム、データ処理方法、及び、データ送信方法
KR102861502B1 (ko) 2018-05-15 2025-09-18 포시 파마슈티컬스 유에스에이 인코포레이티드 기질 금속단백분해효소 (mmp) 억제제 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2021523240A5 (enExample)
CA2913634C (en) Small molecule inhibitors of fibrosis
CA2509981C (en) Hetero substitued sodium channel blockers
AU2003211135B2 (en) Sodium channel blockers
JP2019519598A5 (enExample)
RU2020121150A (ru) Твердые формы ингибитора калликреина плазмы и его солей
RU2006134020A (ru) Конденсированные производные пиразола
JP2021523241A5 (enExample)
JP2014503574A5 (enExample)
MY152955A (en) Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
TW200911232A (en) Novel therapeutic compounds
JP6019126B2 (ja) 有機ニトロチオエーテル化合物およびその医療用途
US10336735B2 (en) Small molecule inhibitors of fibrosis
JP2016199563A (ja) 化学療法または放射線療法によって誘発される嘔吐を予防および／または治療するためのシグマリガンド
JP2022514254A5 (enExample)
JPWO2019031472A1 (ja) 新規アントラニル酸系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤
CA3159791A1 (en) Hexahydro-2h-pyrazino[1,2-a]pyrazine-6,9-dione derivatives and pharmaceutical compositions for prevention or treatment of cancer comprising same
JPWO2019031470A1 (ja) 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤
JP6982716B2 (ja) 複素環式化合物及びその使用
CA2903464A1 (en) Treatment of cancer and other conditions using a transcription factor modulator
RU2010118458A (ru) Производное изоксазола для лечения рака
KR102315866B1 (ko) 섬유화 질환 복합 치료제 개발
KR20110095200A (ko) 신규 5각 헤테로 고리 유도체 및 그 제조방법
JP2017506617A (ja) 未制御細胞成長の阻害のための化合物
RU2801811C1 (ru) Новое соединение и содержащая это соединение фармацевтическая композиция для предотвращения или лечения рака